On Wednesday, 2005 stocks advanced, 2025 declined and 168 remained unchanged on Bombay Stock Exchange with advance decline ...

Infosys Ltd. share price was trading with marginal gains in Wednesday's session ahead of its first quarter-earnings. The Bengaluru-based technology giant is expected to modest topline and Ebitda ...

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

Biocon Biologics launches Nepexto, a biosimilar for autoimmune diseases like rheumatoid arthritis, in Australia. The drug ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...

Biocon advanced 1.34% to Rs 392.25 after the company said that Biocon Biologics (BBL) has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia.

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in ...

- Mylan/Lupin Labs’ Nepexto, a biosimilar of Amgen’s Enbrel (etanercept). The CHMP meeting covered a number of line extensions for already-approved medicines as well, including: ...

Nepexto Market Report 2025 The Business Research Company's Nepexto Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, March 12, 2025 /E... ...